Emergent BioSolutions (EBS) Receivables (2010 - 2026)

Emergent BioSolutions' Receivables history runs 17 years deep, the most recent figure standing at $122.4 million for Q1 2026.

• In Q1 2026, Receivables fell 47.83% year-over-year to $122.4 million; the TTM figure through Mar 2026 stood at $122.4 million (down 47.83% YoY), while the FY2025 annual figure was $102.4 million, down 41.18% from the prior year.
• Receivables was $122.4 million for Q1 2026 at Emergent BioSolutions, up from $102.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $341.9 million in Q2 2023 to a low of $102.4 million in Q4 2025.
• Historically, Receivables has averaged $210.8 million across 5 years, with a median of $230.1 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Receivables soared 48.59% in 2023, then plunged 63.16% in 2025.
• A 5-year view of Receivables shows it stood at $216.4 million in 2022, then grew by 12.01% to $242.4 million in 2023, then declined by 28.18% to $174.1 million in 2024, then tumbled by 41.18% to $102.4 million in 2025, then rose by 19.53% to $122.4 million in 2026.
• The last three Receivables figures came in at $122.4 million (Q1 2026), $102.4 million (Q4 2025), and $168.8 million (Q3 2025), per Business Quant data.